drugset / Trial / NCT02203253
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
Phase 3
Completed
642 enrolled
China Medical University, China
Anshan Tumor Hospital · collabGeneral Hospital of Shenyang Military Region · collabLiaoning Cancer Hospital & Institute · collabLiaoyang Central Hospital · collabPetrochemical General Hospital of Liaoyang city · collabShengjing Hospital · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Hospital of Liaoning Medical University · collabThe Second Affiliated Hospital of Dalian Medical University · collabThird People's hospital Liaoyang · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study was aimed to evaluate efficacy and tolerability of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting in chemotherapy-naive patients after highly emetogenic chemotherapy.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-07
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Thalidomide | Other / unclassified | 100 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 8 mg | Oral |
| Comparator | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |